Business Insights' The Top 10 Generic Pharmaceutical Companies

"Total private and public funding for biotech companies fell by 59.1% in 2008 to a 5 year low of $10.8bn..."

Establishing the most effective exit route for a biotech venture is critical in ensuring value is maximized for key stakeholders and associated technologies. While the biotech venture model has remained relatively unchanged over the past 30 years, the exit strategies employed by companies and venture capitalists are continuously adapting to prevailing market conditions.

Business Insights' special report Biotech Exit Strategies: Delivering value to investors in a challenging funding market provides a comprehensive review of current and future trends in biotech exit strategies and explores the major challenges and key success factors involved in a successful exit. Recent developments in biotech exit strategies are identified and the benefits and challenges associated with various exit routes are evaluated. This report uses 15 case studies of recent biotech exit activity to identify best practices and key learnings for implementing exit strategies, and highlights the main objectives to consider when building an exit path to maximize value for stakeholders.

Click here to view the six-page executive summary of this report.

Examine the latest trends in biotech exit strategies and use detailed case studies to benchmark the exit activities of major companies.

Use this new report as a platform to:

• Compare the key benefits and challenges of different biotech exit routes by evaluating the implications associated with IPO exit strategies; M&A exit strategies, alliances and licensing exit strategies.

• Review 5 in-depth case studies for each major exit strategy to gain insights into the key success factors and major obstacles encountered in recent biotech exit activity.

• Understand key trends in biotech exit strategies, identify the impact of recent developments in biotech funding and productivity, and forecast future funding conditions for biotech companies.

• Understand which indications are likely to generate franchise growth and examine major classes of cancer treatments including antineoplastics, immunostimulants and cytotoxic hormone therapies.

• Identify the main objectives for building a path to exit and understand how to implement a detailed framework for biotech planning and combine the funding lifecycle with exit valuations and interim clinical, commercial and financial parameters.

Click here to view the six-page executive summary of this report.

The report will be delivered as a PDF via e-mail. Orders must be paid in full before shipment. All sales are final; no returns or refunds are permitted with this product. For more information, please call 877/437-4276 or e-mail account manager Maureen Croce at mcroce@hcpro.com.

• Reports

• Other Life Sciences Products